Abstract
BackgroundThere is increasing evidence for the benefit of poly ADP ribose polymerase (PARP) inhibitors in a subset of high-grade serous ovarian carcinoma (HGSC) patients, especially those with homologous recombination (HR)-deficient...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have